Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis licenses anticancer drug to Sarissa
The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies,
The drug is an antisense inhibitor of thymidylate synthase (TS), a well-known drug target that protects cancer cells from the effects of several chemotherapy treatments. In preclinical studies,
KOS-862 (Epothilone D) is a polyketide that inhibits cancer cells by the same mechanism as paclitaxel (marketed as Taxol by Bristol-Myers squibb). Preclinical models have shown the compound
The trial, named STRIDE-2, met its primary endpoint of improved six minute walk (6MW) distance in patients receiving a 100mg dose of Thelin (sitaxsentan), with a placebo-subtracted improvement
The study, published in a peer-reviewed American Cancer Society journal, found that the benefit becomes pronounced within two years of therapy and is maintained throughout its use. Tamoxifen
The UCLA team employed a two-step approach; firstly, the scientists used a version of HIV from which the viral pieces that cause AIDS had been removed. This allowed
The study was co-written by Dr David Graham, one of the FDA’s own scientists and a long-time critic of COX-2 inhibitors such as Merck & Co’s Vioxx and
SOT-107, licensed from Xenova Group, is being developed by Sosei initially for the recurrent form of this brain tumor. The medical need for improved treatment of this disease
This acceptance for filing indicates that the new drug application (NDA) is sufficiently complete to permit a substantive review of the data supporting Xinlay’s safety and effectiveness. Abbott’s
Tev-Tropin (somatropin (rDNA origin) for injection) was clinically tested and FDA-approved for growth hormone deficiency (GHD), and is manufactured by Savient using recombinant DNA (rDNA) technology. Teva has
The study is designed to assess the clinical benefit of using TNFerade in combination with the standard of care treatment. In October 2004, the FDA placed the TNFerade